

What are the differences between Leukemia and Lymphoma



CIBMTR[®] CENTER FOR INTERNATIONAL BLOOD
& MARROW TRANSPLANT RESEARCH



Table of Contents

- Introduction
- Blood Cell Lineages
 - Lymphoid
 - Myeloid
- 4 Main types of Leukemia
- Lymphoma
 - Hodgkins vs. Non-Hodgkins


Hematopoiesis

Myeloid

- Origin- Bone Marrow
- Granulocytes
- White blood cells
 - Neutrophil
 - Eosinophil
 - Macrophages
 - Basophils
 - Megakaryocyte
- Red Blood cells

Lymphoid

- Origin-Bone Marrow
- Lymphocytes
- T-Cells
 - Mature through thymus “teaching”
 - Cell Mediated Immunity
- B-Cells
 - Mature in the Bone Marrow
 - Humoral immune response



Chronic vs. Acute

- **Acute**
 - Symptoms appear and worsen rapidly over time
 - Increase in Blast cells → Non-functional
- **Chronic**
 - Symptoms develop and worsen over an extended period of time (usually)
 - Later stage stem cell differentiation
- **Both**
 - ↑White Blood cells
 - ↓Red Blood cells (Leads to Anemia)
 - ↓Platelets (Bruising/Hemorrhages)

AML and CML


- Acute Myelogenous Leukemia
- Most common type of Leukemia
- Fast growing cancer of the blood and bone marrow
- Characterized by
 - Leukemia cells in the Bone Marrow
 - Blast cells- increased proliferation
- Chronic Myelogenous Leukemia
- Slow growing cancer of white blood cells
- 3 Phases
 - Chronic
 - Accelerated
 - Blast Phase (Sometimes referred to as ALL)
- Characterized by
 - Too many white blood cells
 - Philadelphia chromosome
 - t(9;22)
 - *bcr/abl* gene
 - Makes tyrosine kinase

ALL and CLL

- Acute Lymphocytic Leukemia
- Greatest risk for ALL is in the first 5 years of life
- Fast growing cancer of the blood and bone marrow
- Characterized by
 - Uncontrollable and exaggerated growth of lymphoblasts
 - Also non-functional
 - Blockade of normal marrow cells
- Chronic Lymphocytic Leukemia
- Risk associated with CLL increases rapidly after age 40.
 - 90% Diagnosed over 50
- Can be a very stable disease, some may not received treatment directly after the diagnosis
- Characterized by
 - Staging system (Rai or Binet)
 - # of lymphocytes in blood and marrow
 - Spleen size
 - Lymph node distribution

Lymphomas

- A type of Cancer that begins with a malignant change in a lymphocyte, lymph node cell or lymphatic tissue of the marrow.
- Two Main categories
 - Hodgkins
 - 12% of Lymphoma
 - One of the most curable
 - Presence of Reed-Sternberg cell
 - Distinctive B-lymphocytes
 - Non-Hodkins
 - Majority of lymphoma cases
 - 14 types of B-cell
 - Other types are T-cell and NK cell
 - Spreads through the lymphatic system in a less orderly way



Conclusion

- Both Lymphocytic Leukemia and Lymphoma are the result of a malignant transformation of a cell destined to be a lymphocyte.
 - Distinction(s)
 - The disease started from a lymphocytic cell in a lymph node or other part of the Lymphatic System (LS)
 - Lymphoma
 - The disease started from a lymphocytic cell in Bone marrow (BM)
 - Leukemia
 - In either case, the malignant cells can migrate from their source (BM or LS) and be found in the other.

Conclusion cont.

- Reporting concerns for Forms Net 2.0
 - AML from MDS or MPS
 - Complete entire MDS section on Disease Classification and also complete entire AML section
 - B cell/Small Lymphocytic Lymphoma is reported under CLL
 - CML in Blast Crisis is sometimes referred to as Acute Lymphoblastic Leukemia
 - This is not the case and the disease still should be reported as CML
- Generally the Pre-TED follows World Health Organization (W.H.O.) classifications.

ACUTE LEUKEMIAS

Select most specific W.H.O. classification:

Acute Myelogenous Leukemia (AML)

AML with recurrent genetic abnormalities

- AML with t(8;21)(q22;q22), (AML1/ETO) (281)
- AML with abnormal BM eosinophils and inv(16)(p13q22) or t(16;16)(p13;q22), (CBFβ/MYH11) (282)
- APL with t(15;17)(q22;q12), (PML/RARα) and variants/{M3} (283)
- AML with 11q23 (MLL) abnormalities (284)
- AML with multilineage dysplasia (285)

AML not otherwise categorized/{NOS}

- AML, minimally differentiated/{M0} (286)
- AML without maturation/{M1} (287)
- AML with maturation/{M2} (288)
- Acute Myelomonocytic Leukemia/{M4} (289)
- Acute Monoblastic/Acute Monocytic Leukemia/{M5} (290)
- Acute Erythroid Leukemia (erythroid/myeloid and pure erythroleukemia)/{M6} (291)
- Acute Megakaryoblastic Leukemia/{M7} (292)
- Acute Basophilic Leukemia (293)
- Acute Panmyelosis with Myelofibrosis (294)
- Myeloid Sarcoma (295)
- AML, NOS (280)

Acute Lymphoblastic Leukemia (ALL)

- Precursor B-cell ALL {L1/L2} (191)

If known, indicate subtype:

- t(9;22)(q34;q11); BCR/ABL+ (192)
- t(v;11q23); MLL rearranged (193)
- t(1;19)(q23;p13) E2A/PBX1 (194)
- t(12;21)(p12;q22) ETV/CBF-α (195)
- Precursor T-cell ALL (196)
- ALL, NOS (190)

Acute Leukemias of ambiguous lineage

- Acute undifferentiated leukemia (31)
- Biphenotypic, bilineage or hybrid leukemia (32)
- Acute mast cell leukemia (33)
- Other acute leukemia, (89) specify: _____

SAMPLE

CHRONIC MYELOGENOUS LEUKEMIA (CML)

Philadelphia chromosome+, Ph+, t(9;22)(q34;q11), or variant OR bcr/abl+

Did recipient receive treatment prior to this HSCT? Yes No

(check all that apply) **Mandatory for CIBMTR Research Teams:**

- | | |
|---|--|
| <input type="checkbox"/> Ph+/bcr+ (41) | <input type="checkbox"/> Combination chemotherapy |
| <input type="checkbox"/> Ph+/bcr- (42) | <input type="checkbox"/> Dasatinib (Sprycel) |
| <input type="checkbox"/> Ph+/bcr unknown (43) | <input type="checkbox"/> Hydroxyurea (HU) |
| <input type="checkbox"/> Ph-/bcr+ (44) | <input type="checkbox"/> Imatinib mesylate (Gleevec, Glivec) |
| <input type="checkbox"/> Ph unknown/bcr+ (47) | <input type="checkbox"/> Interferon |
| | <input type="checkbox"/> Nilotinib (Tasigna) |
| | <input type="checkbox"/> Other, specify: _____ |

OTHER LEUKEMIAS

Classification:

Atypical chronic myeloid leukemia {CML, NOS}

- Ph-/bcr/abl- (45)
- Ph-/bcr unknown (46)
- Ph unknown/bcr- (48)
- Ph unknown/bcr unknown (49)

- Chronic Lymphocytic Leukemia (CLL), NOS (34)
- Chronic Lymphocytic Leukemia (CLL), B-cell/
Small Lymphocytic Lymphoma (SLL) (71)
- CLL, T-cell (72)
- Hairy Cell Leukemia (35)
- Prolymphocytic Leukemia (PLL), NOS (37)
 - PLL, B-cell (73)
 - PLL, T-cell (74)
- Other leukemia (39),
specify: _____
- Other leukemia, NOS (30)

Status at Transplantation:

- Never treated
- Complete Remission (CR)
- nodular Partial Remission (nPR)
- Partial Remission (PR)
- No Response/Stable (NR/SD)
- Progression
- Relapse (untreated)

LYMPHOMAS

Classification:

Hodgkin Lymphoma

- Nodular lymphocyte predominant Hodgkin lymphoma (155)
- Lymphocyte-rich (151)
- Nodular sclerosis (152)
- Mixed cellularity (153)
- Lymphoma depleted (154)
- Hodgkin lymphoma, NOS (150)

- Grade I (102)
 - Grade II (103)
 - Grade III (104)
 - Unknown (164)

Non-Hodgkin's Lymphoma

B-cell Neoplasms

- Burkitt's lymphoma/Burkitt cell leukemia {ALL L3} (111)
 - High-grade B-cell lymphoma, Burkitt-like (provisional entity) (135)
- Diffuse large B-cell lymphoma (107)
 - If known, indicate subtype:
 - Intravascular large B-cell lymphoma (136)
 - Mediastinal large B cell lymphoma (125)
 - Primary effusion lymphoma (138)
- Extranodal marginal zone B-cell lymphoma of MALT type (122)
- Follicular lymphoma (includes variants)
- Lymphoplasmacytic lymphoma (121)
- Mantle cell lymphoma (115)
- Nodal marginal zone B-cell lymphoma (+/- monocytoid B cells) (123)
- Primary CNS lymphoma (118)
- Splenic marginal zone B-cell lymphoma (124)
- Waldenstrom macroglobulinemia (173)
- Other B-cell lymphoma (129), specify: _____

SAMPLE

T-cell and NK-cell Neoplasms

- Adult T-cell lymphoma/leukemia (HTLV1+) (134)
- Aggressive NK-cell leukemia (27)
- Anaplastic large-cell lymphoma, T/null cell, primary cutaneous type (147)
- Anaplastic large-cell lymphoma, T/null cell, primary systemic type (148)
- Angioimmunoblastic T-cell lymphoma (AILD) (131)
- Enteropathy-type T-cell lymphoma (133)
- Extranodal NK/T-cell lymphoma, nasal type (137)
- Hepatosplenic gamma-delta T-cell lymphoma (145)
- Mycosis fungoides (141)
- Peripheral T-cell lymphoma {NOS} (130)
- Subcutaneous panniculitis-like T-cell lymphoma (146)
- Sezary syndrome (142)
- Large T-cell granular lymphocytic leukemia (126)
- Other T/NK cell lymphoma (139), specify: _____

Status at Transplantation:

- Never treated